GW Pharmaceuticals PLC Result of AGM (1868E)
February 05 2015 - 8:25AM
UK Regulatory
TIDMGWP
RNS Number : 1868E
GW Pharmaceuticals PLC
05 February 2015
GW Pharmaceuticals plc
Annual General Meeting
London, UK, 5 February 2015: GW Pharmaceuticals plc (AIM: GWP,
NASDAQ: GWPH or the "Company") hereby provides notification that,
at the Annual General Meeting of the Company held earlier today,
all the resolutions set out in the Notice of Meeting sent to
shareholders were duly proposed and passed.
Details of the proxy votes received in relation to each of the
resolutions (which are more particularly described in the Notice of
General Meeting) are as follows:
For Against Total % of votes
votes cast in
favour
--------------- ------------ ----------- ------------ -----------
Resolution 1 188,610,381 442,520 189,430,048 99.77%
--------------- ------------ ----------- ------------ -----------
Resolution 2 166,787,225 22,143,730 189,430,048 88.28%
--------------- ------------ ----------- ------------ -----------
Resolution 3 184,440,444 4,442,827 189,430,048 97.65%
--------------- ------------ ----------- ------------ -----------
Resolution 4 185,543,236 3,490,633 189,430,048 98.15%
--------------- ------------ ----------- ------------ -----------
Resolution 5 185,536,701 3,503,180 189,430,048 98.15%
--------------- ------------ ----------- ------------ -----------
Resolution 6 188,588,260 459,857 189,430,048 99.76%
--------------- ------------ ----------- ------------ -----------
Resolution 7 188,317,170 666,484 189,430,048 99.65%
--------------- ------------ ----------- ------------ -----------
Resolution 8 169,163,586 19,713,744 189,430,048 89.56%
--------------- ------------ ----------- ------------ -----------
Resolution 9 171,245,427 17,677,511 189,430,048 90.64%
--------------- ------------ ----------- ------------ -----------
Resolution 10 169,148,070 19,678,474 189,430,048 89.58%
--------------- ------------ ----------- ------------ -----------
Proxy forms which gave the Chairman and other officers of the
Company discretion have been included in the "For" total.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex(R), which is approved for
the treatment of spasticity due to multiple sclerosis in 27
countries outside the United States. Sativex is also in Phase 3
clinical development as a potential treatment of pain associated
with advanced cancer. GW is also advancing an orphan drug program
in the field of childhood epilepsy with a focus on Epidiolex(R),
which is in Phase 2/3 clinical development for the treatment of
Dravet syndrome and which is also expected to enter Phase 3
clinical trials in the treatment of Lennox-Gastaut syndrome. GW has
a deep pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 clinical development for
glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For
further information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc
Stephen Schultz, VP Investor 917 280 2424 / 401
Relations 500 6570
FTI Consulting (Media enquiries)
Ben Atwell / Simon Conway
/ John Dineen + 44 20 3727 1000
Robert Stanislaro (U.S.) 212 850 5657
Trout Group, LLC (US investor
relations)
Todd James / Chad Rubin 646 378 2900
Peel Hunt LLP (UK NOMAD)
James Steel / Clare Terlouw +44 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGUVUSRVAAURAR
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024
